Table 1.
Baseline Characteristics of Vaccine and Placebo Recipients
| Characteristics | Number (%) | ||
|---|---|---|---|
| Vaccine | Placebo | Total | |
| N = 21 | N = 11 | N = 32 | |
| Gender | |||
| Female | 7 (33%) | 7 (64%) | 14 (44%) |
| Ethnicity | |||
| Hispanic or Latino | 10 (48%) | 4 (36%) | 14 (44%) |
| Not Hispanic or Latino | 11 (52%) | 7 (64%) | 18 (56%) |
| Race | |||
| African American | 10 (48%) | 5 (45%) | 15 (47%) |
| White | 8 (38%) | 5 (45%) | 13 (41%) |
| American Indian | 1 (5%) | 0 (0%) | 1 (3%) |
| More than one race | 0 (0%) | 1 (9%) | 1 (3%) |
| Unknown | 2 (10%) | 0 (0%) | 2 (6%) |
| Residencea | |||
| California | 6 (29%) | 3 (27%) | 9 (28%) |
| Colorado | 6 (29%) | 3 (27%) | 9 (28%) |
| Illinois | 9 (43%) | 2 (18%) | 11 (34%) |
| Maryland | 0 (0%) | 1 (9%) | 1 (3%) |
| New York | 0 (0%) | 2 (18%) | 2 (6%) |
| HIV exposed, uninfected | 14 (67%) | 6 (55%) | 20 (63%) |
| Age in monthsb | 9 (7–14) | 11 (8–16) | 9 (7–16) |
Abbreviations: HIV, human immunodeficiency virus.
aOf the 8 sites, 2 each were in California, Illinois, and New York.
bAge expressed as median (interquartile range).